METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests an experimental oral drug called HP518 in men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapy. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels. About 84 participa…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hinova Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 03:18 UTC
-
New drug cocktails aim to tame tough prostate cancer
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help men with a hard-to-treat form of prostate cancer that has spread and stopped responding to hormone therapy. About 1,200 participants will receive different drug combinations acr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 03:18 UTC
-
New shot every 12 weeks aims to control advanced prostate cancer
Disease control Recruiting nowThis study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New hope for tough prostate cancer: major trial launches
Disease control Recruiting nowThis study tests a new medicine, BMS-986365, against two standard treatments (docetaxel or another hormone therapy) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to hormone therapy. About 960 participants will be random…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
Could a cancer drug shrink prostate tumors in men with a key gene loss?
Disease control Recruiting nowThis study tests the drug bortezomib in men with advanced prostate cancer that has spread and no longer responds to hormone therapy, specifically those with a missing PTEN gene. The main goal is to see if the drug can lower PSA levels by at least 30%. Participants receive bortezo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New study tracks Real-World impact of targeted radiation on prostate cancer Patients' daily lives
Disease control Recruiting nowThis study follows 500 men with metastatic castration-resistant prostate cancer who are receiving a radioactive drug called lutetium (177Lu) vipivotide tetraxetan. Researchers want to see how the treatment affects patients' quality of life, pain, and cancer progression in everyda…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new radioactive drug (177Lu-P17-087/088) in 30 men with advanced prostate cancer that no longer responds to hormone therapy or chemotherapy. The goal is to check safety and find the best dose by giving a single injection and tracking how the drug sp…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
Second dose of targeted radiation shows promise for tough prostate cancer
Disease control Recruiting nowThis study looks at whether giving a second course of a targeted radiation drug (Lu-PSMA) can help control advanced prostate cancer that has stopped responding to hormone therapy. About 58 men who previously benefited from this treatment will receive it again. The goal is to see …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
New drug DS9051b enters first human tests for hard-to-treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called DS9051b in about 40 adults with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 17, 2026 03:15 UTC
-
New hope for tough prostate cancer: first human trial launches
Disease control Recruiting nowThis early-phase study tests an experimental drug called ABBV-969 in men with a hard-to-treat form of advanced prostate cancer (mCRPC). The main goals are to check safety, find the right dose, and see if it lowers PSA levels. About 230 participants worldwide will receive the drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new radioactive drug (177Lu-rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose to shrink tumors or lower PSA levels. About 82 men will take part acr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New hope for hard-to-treat prostate cancer: combo therapy tested in major trial
Disease control Recruiting nowThis study tests whether adding a new drug called xaluritamig to the standard drug abiraterone helps men with advanced prostate cancer live longer. The cancer has spread and no longer responds to hormone therapy, but participants have not yet had chemotherapy. About 750 men will …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New combo therapy aims to slow resistant prostate cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (ZEN003694) to the standard treatment enzalutamide can help men with a certain type of advanced prostate cancer that has stopped responding to another drug (abiraterone). About 200 men will be randomly assigned to receive eithe…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New pill aims to control advanced prostate cancer after standard therapy fails
Disease control Recruiting nowThis study tests an oral drug called XL092 in people with a type of advanced prostate cancer that has spread and stopped responding to a prior treatment (Lu-177-PSMA-617). The main goal is to see if the drug can keep the cancer from growing for at least 16 weeks. About 32 partici…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New combo drug trial aims to control hard-to-treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New hope for advanced prostate cancer: extended targeted radiation trial opens
Disease control Recruiting nowThis study tests a longer course of a radioactive drug (lutetium-177) that targets prostate cancer cells. It is for adults with a specific type of advanced prostate cancer that has stopped responding to hormone therapy but who have not yet had chemotherapy. The goal is to see if …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether adding a radioactive drug (lutetium-177 rosopatamab) to standard treatment helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. About 520 men with PSMA-positive metastatic castration-resistant prostate…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for Hard-to-Treat prostate cancer: early trial launches
Disease control Recruiting nowThis early-phase study tests an experimental drug called BMS-986460 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and stopped responding to standard hormone treatments. The main goals are to check the drug's safety and find…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for tough prostate cancer: drug combo trial begins
Disease control Recruiting nowThis study tests if a combination of two drugs (inavolisib plus enzalutamide) works better than standard treatments for men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 100 men will take part. The goal is to see if the combo ca…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Hope for tough prostate cancer: new combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug darolutamide to standard treatments can help men with a hard-to-treat type of advanced prostate cancer (mCRPC). About 162 participants will receive either standard care alone or standard care plus darolutamide, followed by maintenance ther…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Hormone cycling: a new hope for prostate cancer control?
Disease control Recruiting nowThis study tests a new treatment approach for men with metastatic prostate cancer that has stopped responding to standard hormone therapy. It alternates high-dose testosterone with a drug called darolutamide to see if this cycling can keep the cancer under control longer. About 6…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in men with advanced prostate cancer that has spread and no longer responds to standard treatments. The drug aims to find and destroy cancer cells with radiation. About 60 men will receive up to 6 doses…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests a combination of two drugs: cabozantinib (a pill) and a radioactive drug called 177Lu-PSMA-617 (given through an IV). The goal is to find the safest d…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo aims to boost radiation's punch against hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called JANX007 in men with advanced prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 272 men will take part in this first human study.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Hormone boost followed by radiation: new hope for Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis study tests if giving high-dose testosterone followed by a targeted radiation drug can help men with a tough-to-treat type of prostate cancer that has spread. About 12 participants will take the study drugs for 3.5 months and be followed for 6 months total. The goal is to se…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New prostate cancer drug trial for chinese men
Disease control Recruiting nowThis early-stage study tests a new drug called ASP5541 in about 12 Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to see if the drug is safe and how it is proce…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New radiation therapy aims to shrink tough prostate cancers
Disease control Recruiting nowThis study is for people with metastatic prostate cancer that has spread and is no longer controlled by hormone therapy. It tests a new drug called [212Pb]Pb-ADVC001, which delivers a precise dose of radiation directly to cancer cells. The goal is to find the safest and most effe…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New cell therapy trial targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called A-CAR032 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The treatment uses specially engineered immune cells to attack the cancer. The main goal is to check safety, but researchers…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called datopotamab deruxtecan (Dato-DXd) alone or with other cancer drugs in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gas…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug duo aims to shrink tough prostate tumors
Disease control Recruiting nowThis study tests two experimental drugs, REGN4336 and REGN5678, for men with metastatic castration-resistant prostate cancer that has worsened after prior treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 228 participants will take par…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for tough prostate cancer: first human trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called [225Ac]Ac-FL-020 in 50 people with a hard-to-treat type of prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check the drug's safety and find the right dose. The drug works by targeting …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Full-Life Technologies GmbH • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests if adding an experimental drug (PF-06821497) to a standard treatment (enzalutamide) works better than the standard alone for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 900 participants will be randomly assigned t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for tough prostate cancer: early trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called HRS-5041 in 25 men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to hormone therapy. The main goal is to check the drug's safety and how the body processes it. Participants must h…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for tough prostate cancer: BNT324 takes on chemo in major trial
Disease control Recruiting nowThis study tests if a new drug called BNT324 works better than standard chemotherapy (docetaxel plus steroids) for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 736 men who have already tried one hormone treatment but not chemothera…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug GVV858 shows promise in early trial for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests a new drug, GVV858, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it works better when given alone or with hormone t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug FOG-001 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New drug JANX014 enters first human tests for tough prostate cancer
Disease control Recruiting nowThis early-stage study tests a new drug called JANX014 in about 43 men with a hard-to-treat type of prostate cancer that has spread and no longer responds to hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking for any signs t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New study tracks Pluvicto's Real-World safety for advanced prostate cancer
Disease control Recruiting nowThis study is tracking the safety and effectiveness of the drug Pluvicto in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 278 participants in South Korea will be observed during their normal treatment. The main goal is to recor…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New hope for tough prostate cancer: xaluritamig takes on standard care
Disease control Recruiting nowThis study compares a new drug, xaluritamig, with two standard treatments (cabazitaxel or another hormone therapy) in 675 men with metastatic castration-resistant prostate cancer that has worsened after chemotherapy. The main goal is to see if xaluritamig helps patients live long…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New drug targets Hard-to-Treat prostate cancer in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called FG-3246 in 75 people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The drug is designed to find and attack cancer cells while sparing healthy ones. The goal is to see if it can slow cancer growth an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New radiation therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study is testing a new drug that delivers radiation directly to prostate cancer cells that have spread and stopped responding to hormone therapy. About 95 adults with this advanced cancer will receive the treatment to see if it is safe and what dose works best. T…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New hope for men with hard-to-treat prostate cancer: combo therapy enters trial
Disease control Recruiting nowThis study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the combo can shrink tumors, lower PSA levels, or keep the disease st…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Hormone shots plus vaccine may supercharge immune attack on prostate cancer
Disease control Recruiting nowThis study tests whether adding bipolar androgen therapy (short-term hormone treatment) to the standard Sipuleucel-T vaccine can strengthen the immune system's response against prostate cancer cells. About 26 men with metastatic castration-resistant prostate cancer will receive b…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New SYNC-T therapy shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests a new treatment called SYNC-T therapy (SV-102) in 70 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to find the safest and most effective dose and to see if the treatment can …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New shot could replace daily pills for advanced prostate cancer
Disease control Recruiting nowThis study tests a new injectable form of the hormone therapy abiraterone (ASP5541) in men with advanced prostate cancer that has spread. The shot is given every 12 weeks, instead of daily pills. The goal is to see if it works as well as or better than the standard pill, and to c…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Supercharged immune cells take on End-Stage prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for men with advanced prostate cancer that has spread to the bones and stopped responding to standard therapies. The approach takes a patient's own immune cells (gamma delta T cells), genetically modifies them to better recognize and a…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Promising combo therapy targets hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether combining two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—can slow or stop the growth of advanced prostate cancer that has spread and no longer responds to hormone therapy. About 48 men with this type of cancer…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New chemo combo aims to slow tough-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether adding a second chemotherapy drug (platinum) to the usual treatment (docetaxel) can slow the growth of advanced prostate cancer that no longer responds to hormone therapy. It is for people whose tumors have certain DNA repair gene changes. About 236 parti…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
New approach fights resistant prostate cancer with testosterone flip
Disease control Recruiting nowThis study is testing whether giving testosterone along with an experimental drug (ZEN-3694) first, followed by a standard prostate cancer drug (enzalutamide) plus ZEN-3694, can shrink tumors in men whose prostate cancer has spread and stopped responding to standard treatments. R…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New imaging agent could sharpen view of prostate cancer spread
Diagnosis Recruiting nowThis study involves 30 men with advanced prostate cancer who are already scheduled for a standard treatment called 177Lu-PSMA therapy. Researchers want to see if a newer type of PET scan (18F-DCFPyL) can detect cancer spots as well as the current standard scan (68Ga-PSMA-11). The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 17, 2026 03:10 UTC
-
New PET tracer could reveal which cancers will respond to immunotherapy
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 64Cu-GRIP B that lights up immune activity in PET scans. It aims to see if the tracer is safe and can help detect which advanced cancers (like prostate, kidney, or bladder) are more likely to respond to immunotherapy. About 91 adul…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated May 01, 2026 15:57 UTC
-
Massive prostate cancer registry aims to map Real-World treatment patterns
Knowledge-focused Recruiting nowThis study is a long-term registry that will follow 5000 men with prostate cancer that has come back or spread. It includes four groups: men with a rising PSA after initial treatment, those whose cancer resists hormone therapy but hasn't spread, those with newly spread cancer, an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 17, 2026 03:08 UTC
-
Gut bug may predict prostate cancer drug response
Knowledge-focused Recruiting nowThis study looks at whether a specific gut bacteria, Akkermansia muciniphila, can help predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will measure the bacteria levels in stool samples before and after trea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC
-
Researchers watch how new prostate cancer drug works in everyday clinics
Knowledge-focused Recruiting nowThis study follows 300 men with advanced prostate cancer that no longer responds to hormone therapy. Participants receive a standard treatment called lutetium-177 vipivotide tetraxetan, which delivers radiation directly to cancer cells. The goal is to see how well it works in rea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC
-
Real-world check: does olaparib hold up for tough prostate cancer?
Knowledge-focused Recruiting nowThis study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib as part of their normal treatment. Researchers will track how long patients stay on the drug, how well it controls the cancer, and any side effects. The goal is to see how olap…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC
-
New study tracks Real-World results of prostate cancer combo therapy
Knowledge-focused Recruiting nowThis study observes 250 men with metastatic castration-resistant prostate cancer (mCRPC) who are taking the drugs olaparib and abiraterone together as part of their routine care. Researchers will track how long patients stay on this treatment and what therapies they use next. The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC